Retrophin is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical products and therapies.
The company stated in the following press release that they conduct pre-clinical trials of their drugs on animals.
“RE-024 is a novel small molecule in Phase 1 clinical development as a phosphopantothenate replacement therapy for PKAN. Preclinical findings from studies of PANK-deficient animal models and cell lines suggest the ability of RE-024 to restore CoA levels.” Read the following article
Retrophin, Inc. operates as a biopharmaceutical company, which develops pharmaceutical products for the treatment of rare diseases. It focuses on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. [Source: MarketWatch]
Company Website: http://www.retrophin.com